What if the $611 Million NHS Deal Falls Through?

This article was edited by Andrew Salamon, head of content at Daily Palantir. You can follow him on twitter/x here

Palantir's Stock Woes

In the unpredictable world of corporate contracts and deals, there's always a looming question: what if the anticipated deal doesn’t go through? As we inch closer to the decision regarding the $611 million NHS contract, whispers, speculations, and concerns grow louder surrounding Palantir, the company eyeing the mega deal.

Over the recent months, Palantir's stock took a hit, dropping from 20 dollars to approximately 15 dollars post-earnings release. While many hope for a swift recovery, uncertainties regarding the NHS deal continue to cast a shadow on its potential trajectory.

The NHS Deal: An Overview

For those unfamiliar, the NHS, or the National Health Service, operates as the United Kingdom’s centralized healthcare system, responsible for 67 million individuals' health. Historically, the NHS faced challenges amounting to roughly $10 billion in expenses due to inefficiencies and system backlogs.

In comparison to the US healthcare system, where patients can secure an appointment within a few days, the NHS system, despite its universal healthcare approach, often struggles with longer wait times and bureaucratic red tape.

Palantir aims to streamline this with their proposed $611 million contract, which spans over five years. The goal? To create a federated data platform that amalgamates the NHS's expansive patient and administrative data.

Palantir's track record speaks for itself. They've successfully executed similar projects with Tampa General Bay Hospital and Cleveland Clinic, managing 13% of hospital beds in the United States. However, while the technical capability is evident, two significant challenges could halt Palantir's stride towards securing this deal.

The Challenges Ahead

Firstly, Palantir’s reputation in the UK remains under scrutiny. Despite establishing their headquarters and workforce in the UK, they've battled negative perceptions, fueled partly by organizations like Foxglove. These groups argue that Palantir might misuse sensitive data, painting them as a data-hungry conglomerate, an image the company vehemently disputes.

Secondly, there's growing speculation that the NHS might opt to distribute the contract among multiple tech companies, rather than place all its eggs in the Palantir basket. Such a move, while spreading the risk, could introduce further complexities into the already intricate data integration process.

While Palantir has made significant strides, including a recent $25 million contract from NHS England to transition data to the new platform, uncertainties remain. If Palantir doesn’t secure the entirety of the contract, they might still clinch a part of it.

However, should Palantir miss out entirely, it's not all doom and gloom. The company has a multitude of prospective deals and contracts in the pipeline, including the anticipated Titan contract award and potential S&P 500 inclusion. Moreover, with an impressive 33% YoY growth in international government revenue, the future remains promising for Palantir.

While the NHS deal stands as a monumental opportunity for Palantir, it’s clear that the tech giant has several arrows in its quiver. As the decision date approaches, investors and industry watchers alike will be eagerly watching, hoping for clarity amid these uncertain times.

Thanks for reading the article. If you'd like to get in contact, please @ me on twitter/x here or email me at amit@dailypalantir.com. You can join our Palantir Facebook group here to participate in community discussions, polls, and more. You can check out daily palantir audio content here.